VHL Polyclonal Antibody, PE Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-1367R-PE-100uL |
| Product Name | VHL Polyclonal Antibody, PE Conjugated |
| Applications |
FCM
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Human, Rat |
| Predicted Reactivity | Mouse, Dog, Cow |
| Specifications | |
| Conjugation | PE |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human VHL |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 7428 |
| Subcellular location | Cytoplasm, Nucleus, Cell membrane |
| Synonyms | Von Hippel Lindau; von Hippel-Lindau syndrome protein homolog; Hippel-Lindau disease tumor suppressor VHL; von Hippel-Lindau tumor suppressor isoform 1; VHL; HRCA1; RCA1; VHL1; von Hippel-Lindau disease tumor suppressor isoform 2;pVHL; pVHL; G7 protein; Elongin binding protein; Protein G7; VHL 1; VHL_HUMAN;VHL1; VHLH; Von Hippel Lindau disease tumor suppressor; von Hippel Lindau syndrome; von Hippel Lindau tumor suppressor; Von Hippel-Lindau disease tumor suppressor. |
| Background | Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq]. |
| Application Dilution | |
| FCM | 1:20-100 |
| IF(IHC-P) | |
| IF(IHC-F) | |
| IF(ICC) | |
Frequently asked questions
Which applications is VHL Polyclonal Antibody, PE Conjugated (bs-1367R-PE) validated for, and at what dilution?
bs-1367R-PE is validated for FCM (1:20-100). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does VHL Polyclonal Antibody, PE Conjugated (bs-1367R-PE) react with?
Tested reactivity: Human, Rat. Predicted reactivity (expected from sequence homology but not yet tested): Mouse, Dog, Cow.
How should bs-1367R-PE be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise VHL Polyclonal Antibody, PE Conjugated (bs-1367R-PE)?
KLH conjugated synthetic peptide derived from human VHL
What are the excitation and emission wavelengths of the PE conjugate (bs-1367R-PE)?
PE on bs-1367R-PE: excitation / emission 496,564nm/578nm.